Please assess the completion status of the following clinical trial:

Trial Title: Extension Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Completed Study NS-065/NCNP-01-201 through Week 25.~2. Willing and able to comply with scheduled visits, investigational product administration plan, and study procedures.~3. Stable dose of glucocorticoid (GC), and is expected to remain on the stable dose for the duration of the study.~Exclusion Criteria:~1. Serious or severe adverse event in Study NS-065/NCNP-01-201 that precludes safe use of NS-065/NCNP-01.~2. Patient had a treatment which was made for the purpose of dystrophin or its related protein induction after completion of Study NS-065/NCNP-01-201.~3. Patient took any other investigational drugs after completion of Study NS-065/NCNP-01-201.~4. Patient was judged by the investigator and/or the Sponsor that it was not appropriate to participate in the extension study for other reasons.

- Gender: MALE
- Minimum Age: 4 Years
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- NS-065/NCNP-01 40mg/kg (Type: EXPERIMENTAL): Patients receiving 40mg/kg in the NS-065-NCNP-201 study will continue their current dose for an additional 192 weeks or until enrollment in a separate long-term follow up program of NS-065/NCNP-01, whichever is earlier.
- NS-065/NCNP-01 80mg/kg (Type: EXPERIMENTAL): Patients receiving 80mg/kg in the NS-065-NCNP-201 study will continue their current dose for an additional 192 weeks or until enrollment in a separate long-term follow up program of NS-065/NCNP-01, whichever is earlier.

Based on this trial design, predict the completion outcome and termination type (if applicable).